Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70
- PMID: 15908442
- PMCID: PMC558207
- DOI: 10.1136/bmj.38456.676806.8F
Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70
Abstract
Objective: To investigate the routine use of low dose aspirin in people aged > or = 70 without overt cardiovascular disease.
Design: Epidemiological modelling in a hypothetical population.
Setting: Reference populations of men and women in the year 2000 from the state of Victoria, Australia.
Subjects: 10,000 men and 10,000 women aged 70-74 with no cardiovascular disease.
Main outcome measures: First ever myocardial infarction or unstable angina, ischaemic or haemorrhagic stroke, and major gastrointestinal haemorrhage. Health adjusted years of life lived.
Results: The proportional benefit gained from the use of low dose aspirin by the prevention of myocardial infarctions (-389 in men, -321 in women) and ischaemic stroke (-19 in men and -35 in women) is offset by excess gastrointestinal (499 in men, 572 in women) and intracranial (76 in men, 54 in women) bleeding. The results in health adjusted years of life lived (which take into account length and quality of life) are equivocal for aspirin causing net harm or net benefit.
Conclusion: Epidemiological modelling suggests that any benefits of low dose aspirin on risk of cardiovascular disease in people aged > or = 70 are offset by adverse events. These findings are tempered by wide confidence intervals, indicating that the overall outcome could be beneficial or adverse.
Figures
Comment in
-
Citizen jury should consider aspirin prophylaxis.BMJ. 2005 Jul 16;331(7509):160. doi: 10.1136/bmj.331.7509.160-a. BMJ. 2005. PMID: 16020864 Free PMC article. No abstract available.
Similar articles
-
Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.Ann Intern Med. 2016 Jun 21;164(12):777-86. doi: 10.7326/M15-2129. Epub 2016 Apr 12. Ann Intern Med. 2016. PMID: 27064573
-
Effect of aspirin on mortality in the primary prevention of cardiovascular disease.Am J Med. 2011 Jul;124(7):621-9. doi: 10.1016/j.amjmed.2011.01.018. Epub 2011 May 17. Am J Med. 2011. PMID: 21592450
-
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.Cardiovasc Res. 2021 Feb 22;117(3):942-949. doi: 10.1093/cvr/cvaa100. Cardiovasc Res. 2021. PMID: 32289159 Clinical Trial.
-
Role of aspirin in primary prevention of cardiovascular disease.Nat Rev Cardiol. 2019 Nov;16(11):675-686. doi: 10.1038/s41569-019-0225-y. Epub 2019 Jun 26. Nat Rev Cardiol. 2019. PMID: 31243390 Review.
-
Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force.Ann Intern Med. 2016 Jun 21;164(12):826-35. doi: 10.7326/M15-2112. Epub 2016 Apr 12. Ann Intern Med. 2016. PMID: 27064261 Review.
Cited by
-
Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence.Adv Exp Med Biol. 2021;1286:145-161. doi: 10.1007/978-3-030-55035-6_11. Adv Exp Med Biol. 2021. PMID: 33725352
-
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.N Engl J Med. 2018 Oct 18;379(16):1509-1518. doi: 10.1056/NEJMoa1805819. Epub 2018 Sep 16. N Engl J Med. 2018. PMID: 30221597 Free PMC article. Clinical Trial.
-
The aspirin in reducing events in the elderly trial: Statistical analysis plan.Int J Stroke. 2018 Apr;13(3):335-338. doi: 10.1177/1747493017741383. Epub 2017 Nov 7. Int J Stroke. 2018. PMID: 29111960 Free PMC article. Clinical Trial.
-
Acetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks?Ther Adv Drug Saf. 2012 Oct;3(5):213-26. doi: 10.1177/2042098612451267. Ther Adv Drug Saf. 2012. PMID: 25083237 Free PMC article. Review.
-
Separate prediction of intracerebral hemorrhage and ischemic stroke.Neurology. 2014 May 20;82(20):1804-12. doi: 10.1212/WNL.0000000000000427. Epub 2014 Apr 23. Neurology. 2014. PMID: 24759844 Free PMC article.
References
-
- Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, Kronmal RA. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000;57: 326-32. - PubMed
-
- Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US preventive services task force. Ann Intern Med 2002;136: 161-72. - PubMed
-
- Ridker PM, Cook NR, Lee I-M, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352: 1296-304. - PubMed
-
- Pearson T, Blair S, Daniels S, Eckel RH, Fair JM, Fortmann SP, et al. Guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation 2002;106: 388-91. - PubMed
-
- Dunstan DW, Zimmet PZ, Welborn TA, Cameron AJ, Shaw J, de Courten M, et al. The Australian diabetes, obesity and lifestyle study (AusDiab)—methods and response rates. Diabetes Res Clin Pract 2002;57: 119-29. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical